東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

New approaches to drug discovery

Nielsch, Ulrich.

FindBook

Google Book

Amazon

博客來

New approaches to drug discovery

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	New approaches to drug discovery/ edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
其他作者:	Nielsch, Ulrich.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	viii, 341 p. :ill., digital ;24 cm.
內容註:	Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
Contained By:	Springer eBooks
標題:	Drug development. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-28914-4
ISBN:	9783319289144

New approaches to drug discovery
New approaches to drug discovery[electronic resource] /edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch. - Cham :Springer International Publishing :2016. - viii, 341 p. :ill., digital ;24 cm. - Handbook of experimental pharmacology,v.2320171-2004 ;. - Handbook of experimental pharmacology ;208..

Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

ISBN: 9783319289144

Standard No.: 10.1007/978-3-319-28914-4doiSubjects--Topical Terms:

716904
Drug development.

LC Class. No.: RM301.25

Dewey Class. No.: 615.1072

New approaches to drug discovery
LDR:02742nmm m2200325 m 4500 001 2032397
003 DE-He213
005 20160909092617.0
006 m d
007 cr nn 008maaau
008 161011s2016 gw s 0 eng d
020 $a 9783319289144 $q (electronic bk.)
020 $a 9783319289120 $q (paper)
024 7 $a 10.1007/978-3-319-28914-4 $2 doi
035 $a 978-3-319-28914-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.1072 $2 23
090 $a RM301.25 $b .N532 2016
245 0 0 $a New approaches to drug discovery $h [electronic resource] / $c edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a viii, 341 p. : $b ill., digital ; $c 24 cm.
490 1 $a Handbook of experimental pharmacology, $x 0171-2004 ; $v v.232
505 0 $a Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
520 $a This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
650 0 $a Drug development. $3 716904
650 0 $a Pharmacology. $3 634543
650 0 $a Pharmacy $x Research. $3 686463
650 0 $a Clinical biochemistry. $3 533126
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
650 2 4 $a Medical Biochemistry. $3 892387
650 2 4 $a Metabolomics. $3 1566310
700 1 $a Nielsch, Ulrich. $3 2186393
700 1 $a Fuhrmann, Ulrike. $3 2186394
700 1 $a Jaroch, Stefan. $3 2186395
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Handbook of experimental pharmacology ; $v 208. $3 1567347
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-28914-4
950 $a Biomedical and Life Sciences (Springer-11642)